Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Frank V. Fossella, Scott M. Lippman, Dong Moon Shin et al. · Journal of Clinical Oncology · 1997
PURPOSE: We conducted a phase I trial of the novel nucleoside analog, gemcitabine, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) to determine the maximum-tolerated dose and efficacy in this population. PATIENT AND METHODS: Eligibility requirements included stage III or IV NSCLC, performance status < or = 1, and no prior chemotherapy. Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks every 4 weeks. We enrolled patients at doses that ranged from 1,000 to 2,800 mg/m2/wk (three patients per cohort). Responses were assessed after every two courses (8 weeks). RESULTS: We treated 33 chemotherapy-naive patients with stage III (n = 5) or IV (n = 28) NSCLC. Most had performance status 1, and 67% had adenocarcinoma. Eight of 32 assessable patients (25%) achieved a partial response. The projected median survival duration (all patients) is 49 weeks. The maximum-tolerated dose was 2,200 mg/m2/wk for 3 weeks every 4 weeks; dose-limiting toxicity was myelosuppression and reversible transaminase elevation. Other side effects were consistently mild. The maximum dose-intensity achieved with the first two cycles was 2,362 mg/m2/wk for 3 weeks every 4 weeks, which is a feasible phase II starting dose. CONCLUSION: This study estimates a phase II starting dose of gemcitabine in chemotherapy-naive patients to be 2,400 mg/m2/wk for 3 consecutive weeks every 4 weeks; this is much higher than that previously reported in heavily pretreated patients. Twenty-five percent of patients with advanced NSCLC achieved a partial response to gemcitabine. This significant activity in conjunction with a very favorable toxicity profile supports the further evaluation of gemcitabine in combination with other active agents.
Cited by 127 works. doi:10.1200/jco.1997.15.1.310
Authors
- Frank V. Fossella
- Scott M. Lippman
- Dong Moon Shin
- Peter G. Tarassoff
- M Calayag-Jung
- Roman Perez-Soler
- J S Lee
- William K. Murphy
- Bonnie S. Glisson
- E. Rivera
- Waun Ki Hong
References
- Reporting results of cancer treatment
- Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
- Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
- Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
- 2',2'-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells
- Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.
- Confirmatory activity of gemcitabine in non small cell lung cancer (NSCLC)